Carisma Therapeutics
Philadelphia
About Carisma Therapeutics
Carisma Therapeutics is a biotech company that develops novel chimeric antigen receptor macrophage technology to treat solid tumors. Its cell therapies apply powerful chimeric antigen receptor technology and adoptive cell transfer in cancer therapy and to macrophages that infiltrate the solid tumor micro-environment that enables solid tumor patients to receive strong cellular immunotherapy and cancer treatments.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Total funding: $151.9M
- Funding stage: M&A
- Last round: Series C (Sep 2022)
- Ticker: nasdaq:CARM
- Website: carismatx.com
- Phone: 484-899-0326
Industries & Categories
Biotechnology, Health Care, Life Science, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/carisma-therapeutics-38407 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.